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Autoantibodies (AB) against N-methyl-D-aspartate-receptor subunit-NR1 
(NMDAR1) are highly seroprevalent in health and disease. Symptomatic 
relevance may arise upon compromised blood-brain-barrier (BBB). However, it 
remained unknown whether circulating NMDAR1-AB appear in the 
cerebrospinal fluid (CSF). Of N=271 subjects with CSF-serum-pairs, 26 were 
NMDAR1-AB seropositive, but only 1 was CSF-positive. Contrariwise, tetanus-
AB (non-brain-binding) were present in serum and CSF of all subjects, with 
CSF levels higher upon BBB-dysfunction. Translational mouse experiments 
proved the hypothesis that the brain acts as ′immunoprecipitator′: 
Simultaneous injection of NMDAR1-AB and the non-brain-binding GFP-AB 
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Recently, we reported high seroprevalence (age-dependent up to >20%) of 
autoantibodies (AB) directed against N-methyl-D-aspartate-receptor subunit NR1 
(NMDAR1) in both healthy and neuropsychiatrically ill subjects (N=4236)1. 
Neuropsychiatric syndrome relevance was restricted to individuals with compromised 
blood-brain-barrier (BBB), e.g. APOE4 carrier status or post-neurotrauma, both 
clinically and experimentally2,3. We now wondered whether NMDAR1-AB would be 
similarly seroprevalent in multiple sclerosis (MS) patients with their high likelihood of 
(recurring) BBB disturbance, as indirectly evidenced here as well as in clinical routine 
by an increased albumin quotient, i.e. a disturbed blood-CSF-barrier (BCB)4. In the 
following, the term BBB/BCB will therefore be used throughout. Importantly, we 
asked whether NMDAR1-AB would be present also in the CSF, at least of 





Participants and AB measurements  
MS (N=270) and neuropsychiatric disease control (DC) subjects (N=207) were 
recruited in Magdeburg and Munich for biomarker studies (Table1). Subject data 
were collected in accordance with ethical guidelines and the Helsinki Declaration. 
Sample selection was unbiased, i.e. sera and CSF collection (including determination 
of albumin quotients; Table1) concluded before analysis of AB was planned.  
NMDAR1-AB determination: Commercially available standard procedures for 
clinical diagnosis, recombinant immunofluorescence tests (Euroimmun, Lübeck, 
Germany), were used to detect NMDAR-AB in serum and CSF, based on HEK293 
cells transfected with NMDAR NR1 subunits5,6. Seropositivity for NMDAR1-AB of 
IgG, IgM, or IgA isotypes (using respective second AB against human Ig; 
Euroimmun) was assessed by 2 researchers independently (for sample stainings see 
Figure1)5,6. 
Tetanus-AB determination: Serum and CSF titers of tetanus-AB were measured 
using a tetanus IgG ELISA kit (Sekisui Diagnostics, LLC, USA) over a BioTek EL808 
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ELISA reader (BioTek Instrument GmbH, Bad Friedrichshall, Germany) according to 
manufacturer’s instructions.  
Influenza A and B AB determination: Seropositivity for AB (IgG) was determined 
by ELISA (Novagnost-InfluenzaA-IgG, Novagnost-InfluenzaB-IgG, Siemens 
Healthcare-Diagnostics GmbH, Eschborn, Germany) and automatically processed on 
BEP®III (Siemens Healthcare-Diagnostics GmbH).  
Mouse experiments 
Experiments were approved by the local animal protection committee. Female 
C57Bl/6N ApoE-/- 7 and wildtype littermates (WT; ApoE+/+) mice (N=6 per group), 
aged 14–15 weeks, were housed at 4–5 per cage, 12 h light/dark cycle, food/water 
ad libitum. Mice received an intravenous cocktail of 2 biotinylated monoclonal mouse 
IgG2b AB (150µg each, Synaptic Systems, Göttingen, Germany): (1) directed against 
NMDAR1 (NMDAR1-AB) and (2) against the non-brain-antigen, green fluorescent 
protein (GFP-AB). After 5 days, animals were anesthetized (intraperitoneal injection 
of 0.25% tribromoethanol, 0.125mg/g body weight, Sigma-Aldrich) and CSF, blood, 
brain and spinal cord samples collected and processed for AB titer analysis as 
described in detail in Figure2.  
 
Statistical analysis 
Group differences in categorical and continuous variables were assessed using Chi-
square and Mann-Whitney U test, respectively. Two-way ANOVA was employed to 
assess tetanus AB concentrations by BCB leakage and diagnosis. Statistical 
analyses were performed using SPSS for Windows version 17.0 (IBM-Deutschland 





We confirmed NMDAR1-AB seroprevalence of ~10% (47/477), as expected from 
mean age (all N=477: 38.85±13.1 years) of the cohort8 in both MS (N=270) and DC 
patients (N=207), with an Ig class distribution again similar to that reported earlier1,2: 
4.8% IgM (N=23), 3.1% IgA (N=15), 0.4% IgG (N=2), 1.3% IgA+IgM (N=6) and 0.2% 
IgA+IgG (N=1) (Table1). Also serum titer distributions were comparable between MS 
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and DC (ranging between 1:10 and 1:320) and did not differ dependent on the 
albumin quotient as readout of BBB/BCB leakage (Table1, Figure1A,B).  
 
To further validate our previously reported association of NMDAR1-AB with influenza 
A and B AB seropositivity2, we additionally performed serological analyses for these 
AB. We replicated our earlier result on a new cohort of N=1086 individuals, including 
the subjects of the present study (Table2), strengthening our finding that influenza 
seropositivity is related to the formation of NMDAR1-AB. 
 
In individuals with serum-CSF pairs available (total N=271: N=119 MS; N=152 DC), 
altogether N=26 were seropositive for NMDAR1-AB. Surprisingly, only 1 out of the 
271 CSF samples was positive for NMDAR1-AB (Figure1A). This positive CSF 
sample (IgG; 1:10) was from an MS patient with normal albumin quotient and an 
NMDAR1-AB serum titer of also 1:10 (IgG). In light of the overall low NMDAR1-AB 
serum titers, the negative CSF results of DC might still be somewhat explained by 
the predominantly normal albumin quotients (88.2%). The negative CSF results in 
MS patients with nearly one third confirmed BBB/BCB breakdown (albumin quotient 
pathological in 30.1%), however, were unexpected. In principle, entry of proteins, 
including immunoglobulins, from blood into CSF, does not even require BBB 
breakdown. There are circumventricular organs (organum vasculosum of the lamina 
terminalis, median eminence, area postrema) that lack a BBB and normally allow 
proteins to enter CSF and brain, as demonstrated by the classic studies of Broadwell 
& Brightman using horseradish peroxidase intravenously for tracing9. 
 
We thus hypothesized that the brain may act as ‘immunoprecipitator’ of serum AB 
directed against brain antigens, binding nearly all available AB molecules that pass 
through the BBB, thereby preventing drainage of a detectable amount of NMDAR1-
AB into the CSF. In contrast, AB not expected to specifically bind to brain tissue, 
should appear in measurable amounts in the CSF, with quantities depending on 
BBB/BCB function.  
 
In a first approach to prove this hypothesis, we determined in serum and CSF of our 
cohort the titers of vaccination-induced, abundantly present tetanus-AB (IgG), which 
should not bind to brain antigens. In healthy individuals, the expected transfer over 
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an intact BBB/BCB into the CSF for IgG is 1/500 of the serum concentration4. Indeed, 
Tetanus-AB were detected in all individuals in the CSF, albeit at low levels, 
dependent on serum concentration (Figure1C-D), and by trend also on BBB/BCB 
integrity [δ (rBCB leakage-rBCB intact): Z=-1.502, p=0.06].  
 
In order to experimentally prove our hypothesis of the brain acting as 
′immunoprecipitator′, we employed ApoE-/- mice with their known BBB disruption and 
WT littermates2,7 (Figure2A). In both groups, we simultaneously applied 2 monoclonal 
mouse IgG AB, NMDAR1-AB and GFP-AB (as non-brain-binding AB), intravenously 
in concentrations resulting in serum/plasma titers (previously established by pilot 
experiments) that were theoretically expected to lead to measurable CSF levels even 
in WT mice (IgG 1:10,000 in serum → 1:20 in CSF4).  
 
Five days after application, plasma titers of both AB were lower in ApoE-/- mice with 
their open BBB than in WT littermates (p=0.004). CSF was negative for NMDAR1-AB 
in all mice, but distinctly positive for GFP-AB in 5/6 ApoE-/- mice and 1/5 WT mice. All 
brain regions analyzed in both genotypes were negative for GFP-AB. In contrast, 
NMDAR1-AB were recovered in prefrontal cortex, hippocampus, cerebellum, brain 
stem and spinal cord at high titers mainly in ApoE-/- mice, and to a lesser degree and 
in lower titers in WT mice (Figure2B-C). The recovered titers showed a regionally 
different pattern. This is interesting with respect to the known widespread distribution 
of NMDAR1 all over the central nervous system10-12 and should motivate further 
study. Hitherto unexplained is the overall negative result for the olfactory bulb, even 





The present translational study supports the concept of the brain acting as 
′immunoprecipitator′: Brain-antigen directed AB are strongly bound to brain tissue 
and thereby prevented from drainage into the CSF whereas non-brain bound AB 
appear in the CSF in amounts expected from the literature4. The BBB/BCB intactness 
versus leakiness plays a critical role regarding the titers measured in brain and CSF.  
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Translating these findings to humans with their high NMDAR1-AB seroprevalence 
(age-dependent up to >20%)1,2,8, we may assume that AB crossing over an intact 
BBB at low rate will not cause major symptoms, whereas in situations of acute or 
chronic BBB leakage, the concentrations achieved in brain will eventually become 
symptomatic. The symptoms may then modulate existing disease, e.g. shape the 
presentation of schizophrenia/schizoaffective disorder3 or determine disease 
outcome as shown in stroke, with a reduction of lesion size in individuals with 
previously intact BBB, but detrimental consequence upon pre-existing BBB 
disturbance8. It is well possible that serum NMDAR1-AB may in conditions of 
increasing BBB leakiness (as in aging, e.g.13) contribute to the slow development of 
dementia14. 
 
Importantly, the present data should make clinicians aware that serum NMDAR1-AB 
may modulate brain functions also in absence of measurable titers in CSF. In cases 
where pathological significance of circulating NMDAR1-AB is suspected, the 
BBB/BCB intactness should be tested. This may soon be possible even by routine 
MRI13. In contrast, the high NMDAR1-AB levels reported in CSF of patients with 
NMDAR encephalitis5,15, are likely derived from additional intrathecal synthesis, 
cause high (′oversaturated′) brain levels, severe acute symptoms, and distinct 
spillover into the CSF.  
 
Regarding factors that predispose to NMDAR1-AB formation, we confirmed here our 
previously reported association with influenza A and B seropositivity2. Considerations 
of potential molecular mimicry accounting for this association are still speculative. But 
even though the underlying molecular mechanism is presently unclear, it may help to 
explain the high seroprevalence of NMDAR1-AB with increasing age.  
 
A limitation of the present study is the fact, that mouse experiments were performed 
with IgG AB only. Therefore, kinetics of IgA and IgM in brain/CSF remain subject to 
further work. Nevertheless, in our earlier studies, using IgG, IgA and IgM NMDAR1-
AB derived from human serum in the ApoE-/- mouse model2, a comparable 
consequence of all AB classes could be demonstrated. The same holds true for our 
findings in ischemic stroke patients where the Ig class did not seem to matter 
regarding the effects of serum NMDAR1-AB on evolution of lesion size8. 
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To conclude, our translational study may shed new light on the understanding of 
potential symptomatic consequences of serum AB directed against brain antigens. 
Whereas leakiness of the BBB has a major role and should be evaluated in cases 
where pathological relevance of circulating NMDAR1-AB is suspected, negative 
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Figure 1: Human data. (A) NMDAR1-AB titer distribution in serum and CSF 
presented by diagnosis and BBB/BCB integrity. Titer distribution in serum (IgM 
purple, IgA yellow, IgG turquois dots) was comparable between multiple sclerosis 
patients (MS) and neuropsychiatric disease controls (DC) and did not differ 
dependent on BCB leakage. Only 1 CSF sample of an MS patient was 1:10 positive 
(IgG, respective serum titer of this patient circled). Please note that numbers in 
circles plus dots do not always add up to the numbers given for the groups since 
individual patients may carry AB of 2 Ig classes. (B) Representative confocal images 
of HEK293 cells transfected with NMDAR1 (Euroimmun) as used for serum and CSF 
tests. NMDAR1-AB seropositivity is illustrated as an example for 3 different patients 
(using anti-human IgG, IgM or IgA, FITC-labeled as second AB), including the 
subject with the only positive CSF sample (IgG). All images are Z projections of 10 
focal planes located 0.5 µm apart and were taken at 63X magnification under a 
confocal laser scanning microscope (Leica SP5). (C) Intercorrelation of tetanus-AB in 
CSF and serum in MS and DC, stratified by BBB/BCB integrity. Tetanus-AB were 
detected in all individuals in the CSF, albeit at low levels, dependent on serum 
concentration and BBB/BCB integrity. Pearson correlation coefficients are shown. (D) 
Two-way ANOVA, with tetanus-AB levels in serum and CSF as dependent variables 
and BBB/BCB integrity and diagnosis as factors, resulted in a main effect for 
BBB/BCB integrity while diagnosis and interaction of both factors were not significant.  
 
Figure 2: Mouse data. (A) Experimental design: Female C57Bl/6N ApoE-/- mice7 and 
their wildtype littermates (WT, ApoE+/+), received an intravenous cocktail of 2 
biotinylated monoclonal mouse IgG2b AB (NMDAR1-AB and, as non-brain-antigen 
directed AB, GFP-AB; 150µg each). After 5 days, animals were anesthetized and 
samples were taken. CSF (1-2 µl) was collected from the cisterna magna using a 
glass capillary. Blood (0.5ml) was drawn from the left ventricle of the heart and then 
processed as indicated in the figure to obtain the plasma. Brain and spinal cord were 
freshly extracted and dissected under a stereomicroscope and quickly processed as 
described in the figure, following a previously described protocol16 to obtain IgG 
extracts from tissue. AB titers in CSF, plasma and brain/spinal cord extracts were 
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determined using cell-based assays: Samples were tested in different dilutions (from 
1:10 to 1:10,000) on HEK293 cells transfected with either NMDAR1 (Euroimmun) or 
GFP (self-made; pEGFP-N1 4.7 kb plasmid, Lipofectamine 2000) and on HEK293 
non-transfected cells (negative controls). Titer was defined as the last dilution in 
which positivity was observed (green and red co-localizing label, see diagram in A 
and confocal pictures in B). (B) Representative images showing positivity/negativity 
observed for NMDAR1 and GFP in different samples (abbreviations given refer to 
those in C, too). Note the co-localization of green (anti-mouse IgG-A888) and red 
(rabbit anti-biotin + anti-rabbit-A594) in all positive cases, demonstrating the high 
specificity of the test. (C) Titer distributions of NMDAR1-AB and GFP-AB dependent 
on genotype (ApoE-/- mice with their leaky BBB and ApoE+/+ with intact barrier) and 
respective p-values (Mann-Whitney U test). Note that plasma titers of both AB were 
lower in ApoE-/- mice (p=0.004). CSF (due to restricted material only tested at 1:10) 
was negative for NMDAR1-AB in all mice, but distinctly positive for GFP-AB in 5/6 
ApoE-/- mice and only 1/5 WT mice. All brain regions analyzed in both genotypes 
were negative for GFP-AB. In contrast, NMDAR1-AB were recovered in prefrontal 
cortex, hippocampus, cerebellum, brain stem and spinal cord in high titers mainly of 
ApoE-/- mice, and to a lesser degree and in lower titers in WT mice.  
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Total sample (only serum available; N=477) 
Subsample with serum and  
cerebrospinal fluid available (N=271) 
  Disease controls
a
 Multiple Sclerosis p value Disease controls
b
 Multiple Sclerosis p value 
 
 
N=206-207 N=263-270  N=104-152 N=113-119  
        
Gender, No. (%), women
c
  150 (72.5) 178 (66.9) 0.194 109 (71.7) 82 (70.7) 0.855 
        Age at examination, mean ± SD, years
d
  38.8 ± 14.5 38.8 ± 11.8 0.559 38.9 ± 15.3 37.1 ± 12.2 0.576 
        Disease course (Multiple Sclerosis), No. (%)        
Clinically isolated syndrome   n/a 56 (21.2) 
n/a 
n/a 37 (31.9) 
n/a 
Relapsing remitting   n/a 156 (59.1) n/a 47 (40.5) 
Primary progressive  n/a 21 (8) n/a 15 (12.9) 
Secondary progressive  n/a 31 (11.7) n/a 17 (14.7) 
        Duration of disease (MS), mean ± SD, months  n/a 96.2 ± 68.6 n/a n/a 105.5 ± 17.3 n/a 
        No. of relapses (MS), No. (%)        
No relapse  n/a - 
n/a 
n/a 16 (13.9) 
n/a 1 relapse  n/a - n/a 47 (40.9) 
2 or more relapses  n/a - n/a 52 (45.2) 
        No. of clinical MRI lesions (MS), No. (%), 2 or more 
e
   n/a - n/a n/a 82 (71.3) n/a 
        Expanded Disability Status Scale (MS), mean ± SD  n/a - n/a n/a 3.2 ± 1.1 n/a 
        NMDAR1-AB serostatus, No. (%), seropositive
c
  19 (9.2) 28 (10.4) 0.665 14 (9.2) 12 (10.1) 0.809 
        NMDAR1-AB seroprevalence, titers, No.
 c, f
        
        IgA (1:10; 1:32; 1:100; 1:320)   4; 2; 3; 1 5; 6; 0; 1 0.174 3; 0; 3; 1 2; 4; 0; 0 0.043 
IgG (1:10; 1:32; 1:100; 1:320)  0; 0; 0; 0 2; 1; 0; 0 - 0; 0; 0; 0 1; 1; 0; 0 - 
IgM (1:10; 1:32; 1:100; 1:320)  2; 5; 3; 0 2; 3; 4; 0 0.606 1; 4; 3; 0 1; 6; 2; 0 0.762 
        Albumin quotient, mean ± SD
d
  n/a n/a n/a 5.0 ± 1.7 6.2 ± 3.6 0.004 
        Blood-cerebrospinal fluid barrier, No. (%), leakage
c, g
  n/a n/a n/a 18 (11.8) 34 (30.1) 0.0002 
        Tetanus titers in serum (IU/ml), mean ± SD
d
  n/a n/a n/a 2.3 ± 1.3 2.1 ± 1.5 0.198 
        Tetanus titers in cerebrospinal fluid (IU/ml), mean ± SD
d
  n/a n/a n/a 0.003 ± 0.003 0.005 ± 0.005 0.032 
        
Multiple testing adjusted significances (Bonferroni: p≤0.008 for the sample with serum available and p≤0.005 for the subsample with serum and cerebrospinal fluid available); 
a
this category includes neurodegenerative 
disorders (12.6%), psychiatric conditions (33.8%), healthy or minor conditions not relevant for cerebrospinal fluid pathology (41%) and others (12.6%); 
b
this category includes neurodegenerative disorders other than 




Mann-Whitney U test;  
e
all other 
individuals have one MRI lesion;  
f
Note that of the total sample N=4 individuals were seropositive for both IgA and IgM; 
g
blood-cerebrospinal fluid barrier was diagnosed as ‘leakage’ when albumin quotient >age/15+4; 
abbreviations: n/a= not applicable   
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Hammer et al  2013  
(N=2805)* 
NMDAR1-AB serostatus 
- + - + - + - + - + - + - + - + 
N=241 N=26 N=142 N=19 N=364 N=100 N=69 N=12 N=68 N=3 N=39 N=3 N=923 N=163 N=2522 N=295 
                  

































 P value 0.487 0.064 0.128 0.134 0.499 0.397 0.018 0.024 
 OR (95% CI) 1.02 (0.40-2.84) 3.22 (0.71-14.58) 1.38 (0.79-2.40) 3.32 (0.40-27.72) n/a 1.38 (0.12-16.68) 1.59 (1.03-2.45) 1.37 (1.04-1.79) 
                  
NMDAR1-AB serostatus 
- + - + - + - + - + - + - + - + 
N=241 N=26 N=142 N=19 N=364 N=100 N=69 N=12 N=68 N=3 N=39 N=3 N=923 N=163 N=2522 N=295 
                  

































 P value 0.085 0.330 0.085 0.302 0.374 0.499 0.034 0.006 
 OR (95% CI) 1.83 (0.78-4.35) 1.28 (0.43-3.82) 1.46 (0.85-2.5) 1.41 (0.40-5.28) 1.5 (0.13-17.6) n/a 1.45 (0.97-2.15) 1.45 (1.11-1.90) 
          
 
One-sided P values are shown for the replication study cohorts; bolded values, p<0.05; +, NMDAR1-AB seropositive; -, NMDAR1-AB seronegative; OR, odds ratio; CI, confidence 
intervals; n/a, not applicable;  * data from the original study (discovery sample) by Hammer et al 2013 for comparison (two-sided P values) 
 
Note regarding the replication sample:  MS and DC patients are from the present study (numbers smaller due to reduced serum availability), stroke patients from Zerche et al 
2015; AD patients, other psychiatric diagnoses and healthy controls from the extended GRAS data collection. 
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